Evidence map›Paper›PMID 37577527›Full record

ArticlebioRxiv : the preprint server for biology2024

Alzheimer's disease linked Aβ42 exerts product feedback inhibition on γ-secretase impairing downstream cell signaling.

Katarzyna Marta Zoltowska, Utpal Das, Sam Lismont, Thomas Enzlein, Masato Maesako, Mei Cq Houser, María Luisa Franco, Burcu Özcan, Diana Gomes Moreira, Dmitry Karachentsev and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Katarzyna Marta ZoltowskaVIB-KU Leuven Center for Brain & Disease Research, VIB, Leuven, Belgium.ORCID 0000-0001-5853-3465
Utpal DasDepartment of Neurosciences, University of California San Diego, La Jolla, CA, United States of America.ORCID 0000-0002-1635-9849
Sam LismontVIB-KU Leuven Center for Brain & Disease Research, VIB, Leuven, Belgium.ORCID 0000-0001-5825-9590
Thomas EnzleinVIB-KU Leuven Center for Brain & Disease Research, VIB, Leuven, Belgium.ORCID 0000-0003-1789-4090
Masato MaesakoDepartment of Neurology, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, United States of America.ORCID 0000-0002-1970-2462
Mei Cq HouserDepartment of Neurology, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, United States of America.
María Luisa FrancoMolecular Basis of Neurodegeneration Unit, Institute of Biomedicine of València (IBV-CSIC), València, Spain.
Burcu ÖzcanVIB-KU Leuven Center for Brain & Disease Research, VIB, Leuven, Belgium.
Diana Gomes MoreiraVIB-KU Leuven Center for Brain & Disease Research, VIB, Leuven, Belgium.ORCID 0000-0003-2937-1772
Dmitry KarachentsevDepartment of Neurosciences, University of California San Diego, La Jolla, CA, United States of America.
Ann BeckerDepartment of Neurosciences, University of California San Diego, La Jolla, CA, United States of America.
Carsten HopfCenter for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim, Germany.ORCID 0000-0003-0802-6451
Marçal VilarMolecular Basis of Neurodegeneration Unit, Institute of Biomedicine of València (IBV-CSIC), València, Spain.ORCID 0000-0002-9376-6544
Oksana BerezovskaDepartment of Neurology, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, United States of America.ORCID 0000-0003-4898-5788
William MobleyDepartment of Neurosciences, University of California San Diego, La Jolla, CA, United States of America.ORCID 0000-0002-6408-9548
Lucía Chávez-GutiérrezVIB-KU Leuven Center for Brain & Disease Research, VIB, Leuven, Belgium.ORCID 0000-0002-8239-559X
VIB-KU Leuven Center for Brain & Disease Research · BEUniversity of California San Diego · USHarvard University · USInstituto de Biomedicina de Valencia · ESTechnische Hochschule Mannheim · DE

Funding

TRANSGENICS AND PRESENILIN FUNCTIONP01AG015379 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BEREZOVSKA, OKSANA · 1998 to 2023
$51.3M
Multiplexed Single Nucleus RNA and ATAC-seq Sequencing and Cortical Organoids: Transformative Insights into Down SyndromeR01AG070154 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MOBLEY, WILLIAM C, ROSENFELD, MICHAEL G · 2020 to 2020
$5.0M
Role of PS1 in neurodegenerationRF1AG044486 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BEREZOVSKA, OKSANA · 2019 to 2019
$3.2M
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer DiseaseR01AG055523 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MOBLEY, WILLIAM C · 2018 to 2022
$3.2M
Role of PS1 in neurodegenerationR01AG044486 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BEREZOVSKA, OKSANA · 2014 to 2018
$2.5M
NIA NIH HHS P01 AG015379NIA NIH HHS R01 AG044486NIA NIH HHS R01 AG055523NIA NIH HHS R01 AG070154NIA NIH HHS RF1 AG044486
6 · The paper itself

Abstract

Amyloid β (Aβ) peptides accumulating in the brain are proposed to trigger Alzheimer's disease (AD). However, molecular cascades underlying their toxicity are poorly defined. Here, we explored a novel hypothesis for Aβ42 toxicity that arises from its proven affinity for γ-secretases. We hypothesized that the reported increases in Aβ42, particularly in the endolysosomal compartment, promote the establishment of a product feedback inhibitory mechanism on γ-secretases, and thereby impair downstream signaling events. We show that human Aβ42 peptides, but neither murine Aβ42 nor human Aβ17-42 (p3), inhibit γ-secretases and trigger accumulation of unprocessed substrates in neurons, including C-terminal fragments (CTFs) of APP, p75 and pan-cadherin. Moreover, Aβ42 treatment dysregulated cellular -homeostasis, as shown by the induction of p75-dependent neuronal death in two distinct cellular systems. Our findings raise the possibility that pathological elevations in Aβ42 contribute to cellular toxicity via the γ-secretase inhibition, and provide a novel conceptual framework to address Aβ toxicity in the context of γ-secretase-dependent homeostatic signaling.

Indexed as

Alzheimer’s diseaseamyloid betaamyloid toxicitygamma-secretasepresenilin

Identifiers

PMID37577527
PMCPMC10418207
OpenAlexW4385551829

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.